Coloplast expands Executive Leadership Team Today, the Board of Directors have decided to expand the Coloplast Executive Leadership Team (ELT) with immediate effect.

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Atossa Therapeutics (ATOS – Research Report) today and set a price target ...

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to ...

Detailed results from the KARISMA-Endoxifen trial demonstrating (Z)-endoxifen’s ability to significantly reduce mammographic breast density to be featured at conferenceSEATTLE, Nov. 20, 2024 ...

Atos has a 12-month low of $0.37 and a 12-month high of $8.53. The stock’s 50-day moving average price is $0.89 and its two-hundred day moving average price is $1.77. 10 Stocks to Sell NOW! 3 ...

France stepped up efforts on Friday to protect Atos (ATOS.PA), opens new tab, the country's struggling and debt-ridden software company which is undergoing a restructuring. The parliament's ...

Atos said on Tuesday it had signed an agreement to sell its Worldgrid business unit to Alten for 270 million euros ($293.7 ...

France Steps up Efforts at Examining How to Protect Struggling IT Company Atos PARIS (Reuters) - France stepped up efforts on Friday to protect Atos, the country's struggling and debt-ridden ...

PARIS (Reuters) - France stepped up efforts on Friday to protect Atos, the country's struggling and debt-ridden software company which is undergoing a restructuring. The parliament's Finance ...

Mustier will be replaced from February by Philippe Salle, Atos' sixth CEO in less than two years, who has pledged to invest 9 million euros in the company's ongoing restructuring. The company's ...

Atos SE said a French commercial court approved its financial restructuring plan, paving the way for creditors to take control of the troubled French IT company in the coming months. Under the ...